Are You A Pro? Join For Free

Daryl Boyd

Arthrogen, GmbH

Contact Information:

Years in Business:



Clients I'm Seeking:


Human and Equine Regeneration

About My Business:


***************************************************************** CONSIDER FORGETTING FOR A MOMENT WHAT YOU KNOW OF HUMAN AND ANIMAL REGENERATION ! The Plasma Gelsolin Protein has been researched for over 20 years by PhD's at Harvard, Stanford, University of Toronto, University of Florida, University of Pennsylvania (to name a few) in over 1,988 studies Published on PubMed ( Predictions have been made that pGelsolin could reverse Alzheimer's, Parkinson's, Diabetes, AIDS, Cancers, Neurodegeneration Following Ischemic Stroke, Anti Aging and Regeneration Therapies [Published online 9 November 2010 in Wiley Online Library (] Professor Dr. Ulrich Schneider discovered that our Arthrogen, GmbH GOLDIC Enhanced Gelsolin Product increases the protein Gelsolin level in autologous blood by up to 12 Times. Arthrogen, GmbH GOLDIC Enhanced Gelsolin Wakes UP Stem Cells in the Injured tissue to begin repair, and then goes beyond Repairing to REGENERATION of Tendinitis, Lameness, Spine Disc Herniation, Pain, Cartilage - Tendon - Muscle - Ligament Injuries in Humans *********************************** DECREASE OF THE GELSOLIN PROTEIN IS THE CAUSE OF INFLAMMATORY DISEASE, NOT (IRAP) INTERLEUKIN 1 RECEPTOR ANTAGONIST OR UNDIFFERENTIATED STEM CELLS OR (PRP) PLATELET RICH PLASMA SIMPLY REPLACE THE GELSOLIN, AND REGENERATE INJURIES ! The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis). Plasma gelsolin (pGSN) Concentration is Decreased in Patients with Rheumatoid Arthritis (RA) Compared to Healthy Controls and Lower in Synovial Fluid than in Blood in Patients with RA We measured plasma gelsolin (pGSN) levels in patients with rheumatoid arthritis (RA) to experimentally test the hypothesis that plasma gelsolin levels fall in response to the initial (unknown) injury inflicted by the agency causing rheumatoid arthritis. As shown in FIG. 1, circulating (pGSN) levels were significantly lower in patients with RA compared to matched healthy controls (103±23 versus 142±29, P=0.0002, FIG. 1). pGSN levels were similar in both male and females, and were not dependent on the age of the patients or on the duration of arthritis. Circulating pGSN levels were inversely correlated to the levels of C-reactive protein (1=-0.272, p=0.026). This invention is based on the surprising discovery that plasma gelsolin levels are reduced in blood samples from human subjects with an inflammatory disease, rheumatoid arthritis (RA). These findings support the hypothesis that reductions in plasma gelsolin levels reflect the primary injury inflicted on joint tissues by the causative agency of rheumatoid arthritis and precede joint pain and destruction by the resultant inflammatory process. These observations provide a basis for treatment with gelsolin to prevent and/or suppresses the manifestations of inflammatory diseases. One correlate of these observations is that monitoring of plasma gelsolin levels could become part of the management strategy of rheumatoid arthritis. Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis Publication number US8198094 B2 Publication type Grant Application number US 12/225,128 PCT number PCT/US2007/006451 Publication date Jun 12, 2012 Filing date Mar 15, 2007 Priority date Mar 15, 2006 Also published as CA2680413A1, 7 More » Inventors Thomas P. Stossel, Teresia Anna Charlotta Magnuson Osborn, Andrej Tarkowski Original Assignee The Brigham And Women's Hospital, Inc. Export Citation BiBTeX, EndNote, RefMan *****************************************************************

Years in business:
Member since:
Clients I'm looking for: